Radiation therapy for oligometastatic bone disease in breast cancer

Norihisa Katayama, Kuniaki Katsui, Kenta Watanabe, Ryota Nagao, Kaho Otsuki, Takao Hiraki, Susumu Kanazawa

Department of Radiology, Okayama University Medical School, Okayama, Japan

Contributions: (I) Conception and design: N Katayama, K Katsui, K Watanabe, T Hiraki, S Kanazawa; (II) Administrative support: T Hiraki, S Kanazawa; (III) Provision of study materials or patients: N Katayama, K Watanabe, R Nagao, K Otsuki; (IV) Collection and assembly of data: N Katayama, K Watanabe, R Nagao, K Otsuki; (V) Data analysis and interpretation: N Katayama, K Watanabe, R Nagao, K Otsuki; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Norihisa Katayama, MD, PhD. Department of Radiology, Okayama University Medical School, 2-5-1 Shikata-cho, Okayama 700-8558, Japan. Email: n-katayama@bea.hi-ho.ne.jp.

Abstract: Breast cancer (BCa) frequently metastasizes to the bone. BCa patients with oligometastatic bone diseases have much more favorable outcomes than those with metastatic bone disease. Radiation therapy (RT), especially stereotactic body radiation therapy (SBRT), is advised for the treatment of patients with oligometastatic bone disease in other primary sites. This line of treatment provided favorable outcomes in patients and resulted in only mild toxicities. A similar strategy has been suggested for treatment of BCa patients with oligometastatic bone disease. BCa, bone-only, or high radiation dose are reported to have been associated with good outcomes in RT for metastatic disease. Furthermore, based on the guidelines provided by the BCa expert panel of the German Society for Radiation Oncology and members of the Working Party of Gynecologic Oncology Breast Committee and in line of the results obtained in other primary sites, our group supports the use of high-dose RT or SBRT for the treatment of BCa patients with oligometastatic bone disease. Additionally, the use of magnetic resonance imaging (MRI) for proper target volume definition and three-dimensional (3D) treatment planning especially for lesions of the trunk are essential for the treatment planning of RT. Of note, several clinical trials have combined RT with immune checkpoint inhibitors for the treatment of BCa patients with metastatic disease. Based on this, we anticipate that combined RT and ICI may serve as a better treatment modality for BCa patients with oligometastatic bone disease.

Keywords: Bone metastasis; breast cancer (BCa); oligometastatic; radiation therapy (RT); stereotactic body radiation therapy (SBRT)

Submitted Dec 13, 2019. Accepted for publication Jan 06, 2020.
doi: 10.21037/tcr.2020.01.35

View this article at: http://dx.doi.org/10.21037/tcr.2020.01.35

Introduction

Bone is the most common site for metastasis in breast cancer (BCa) (1). In about 20% of the patients, tumors of the breast metastasize to the bone. Moreover, bone metastasis (BM) occurs in more than half of the cases showing distant metastases (2). Additionally, up to 70% of the patients who succumb to BCa show evidence of metastatic bone disease, post-mortem (3). BCa patients with first BM have a median survival time of about 20 months, and a 10% 5-year survival rate (4). Whereas, the 5-year survival rate for BCa patients with singular or oligometastatic bone disease is in the favorable range of 58.4–83% (5-7).

The treatment of patients with BM includes the systemic administration of antitumor and antiresorptive agents, and/or localized radiation therapy (RT), radiofrequency ablation,
and surgery. RT especially plays an important role due to the radiosensitivity of BCa cells (8). Pain, limited movements, risk of fracture, after surgical intervention, and spinal cord compression are the indications for palliative RT (9). While pain relief is generally observed within a few days after the start of RT, radiologically detectable recalcification and stabilization commence at the earliest within 6–12 weeks after termination of RT. Moreover, asymptomatic patients with favorable prognostic factors can be treated using RT (10). Furthermore, high-dose RT may provide long-term localized control from skeletal manifestations and improve the overall survival (OS) of patients with oligometastases.

Here, we have described RT for the treatment of patients with oligometastatic bone disease in other primary sites and in BCa, and the future perspectives.

**RT for oligometastatic bone disease in other primary sites**

Some studies have opted RT for oligometastatic bone disease in other primary sites (Table 1) (11-20), and 8 of these 10 studies have used stereotactic body radiation therapy (SBRT). Sixty-seven percent of Grade ≥3 toxicities were fractures requiring a surgery. Overall, they resulted in excellent outcomes with mild toxicities.

A recent SABR-COMET randomized phase II study (21) has compared the responses to SBRT (30–60 Gy in 3–4 fractions or 16–24 Gy in single fraction) and conventional RT (8 Gy in single fraction to 30 Gy in 10 fractions) in 99 patients who had a controlled primary malignancy with 1–5 metastatic lesions in mixed primary sites. Amongst these, about 33.5% account for metastases to the bone. The median OS in the conventional RT group was 28 months as compared to 41 months in the SBRT group (P=0.090; where P<0.20 designates a positive trial). Adverse events of grade 2 or worse occurred in 9% of conventional RT group compared to 29% in the SBRT group (P=0.026). Additionally, treatment-related deaths occurred in 4.5% cases in the SBRT group, while no deaths occurred in the conventional RT group.

Several studies recommend SBRT for treatment of oligometastatic bone disease (22-31). The American College of Radiology Appropriateness Criteria suggests that aggressive local therapy of oligometastatic spine disease may provide survival benefit to the patients, although additional data would be required to understand the role of highly conformal RT techniques that allow for radiation dose escalation (32). The evidence-based guidelines of The American Society for Radiation Oncology (ASTRO) do not describe the use of curative intent SBRT for treatment of

### Table 1 RT for oligometastatic bone disease in other primary sites

<table>
<thead>
<tr>
<th>Author, year</th>
<th>No. of patients</th>
<th>Histology</th>
<th>RT dose and fractionation</th>
<th>Local control outcomes</th>
<th>Survival outcomes</th>
<th>Grade ≥3 toxicity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patel et al. (11), 2019</td>
<td>51</td>
<td>Prostate</td>
<td>10 Gy x3, SBRT</td>
<td>90% (3 years)</td>
<td>73% (4 years)</td>
<td>0</td>
</tr>
<tr>
<td>Silva et al. (12), 2019</td>
<td>20</td>
<td>Mixed</td>
<td>8–10 Gy x3, 5–8 Gy x5, SBRT</td>
<td>100% (1 year)</td>
<td>NR</td>
<td>5%</td>
</tr>
<tr>
<td>Siva et al. (13), 2018</td>
<td>20</td>
<td>Prostate</td>
<td>20 Gy x1, SBRT</td>
<td>89% (2 years)</td>
<td>100% (2 years)</td>
<td>3%</td>
</tr>
<tr>
<td>Hosaka et al. (14), 2016</td>
<td>27</td>
<td>Mixed</td>
<td>37.5–60 Gy</td>
<td>64.3% (4 years)</td>
<td>56.3% (4 years)</td>
<td>NR</td>
</tr>
<tr>
<td>Ursino et al. (15), 2015</td>
<td>28</td>
<td>Mixed</td>
<td>24 Gy x1, 9 Gy x3, SBRT</td>
<td>69% (3 years)</td>
<td>71.7% (3 years)</td>
<td>2.5%</td>
</tr>
<tr>
<td>Owen et al. (16), 2014</td>
<td>74</td>
<td>Mixed</td>
<td>18 or 24 Gy x1, 10 Gy x3, SBRT</td>
<td>91.8% (1 year)</td>
<td>81.4% (1 year)</td>
<td>0</td>
</tr>
<tr>
<td>Thibault et al. (17), 2014</td>
<td>13</td>
<td>Renal cell cancer</td>
<td>18–24 Gy x1, 10–12 Gy x2, SBRT</td>
<td>61% (2 years)</td>
<td>73% (2 years)</td>
<td>6.6%</td>
</tr>
<tr>
<td>Muacevic et al. (18), 2014</td>
<td>40</td>
<td>Prostate</td>
<td>16.5–22 Gy x1, SBRT</td>
<td>95.5% (2 years)</td>
<td>*</td>
<td>NR</td>
</tr>
<tr>
<td>Wowra et al. (19), 2008</td>
<td>102</td>
<td>Mixed</td>
<td>15–24 Gy x1, SBRT</td>
<td>98% (1.25 years)</td>
<td>68% (1.25 years)</td>
<td>2.0%</td>
</tr>
<tr>
<td>Rades et al. (20), 2007</td>
<td>521</td>
<td>Mixed</td>
<td>8 Gy x1, 3 Gy x10, 2 Gy x20</td>
<td>78% (3 years)</td>
<td>50% (3 years)</td>
<td>0</td>
</tr>
</tbody>
</table>

*, the 75% survival proportion was achieved at 17.5 months. RT, radiation therapy; SBRT, stereotactic body radiotherapy; NR, not reported.
oligometastatic bone disease (33). Instead, the guidelines suggest that eligible patients with metastases to the spine be considered for available SBRT trials to clarify the role of optimal treatment approach.

RT for oligometastatic bone disease in BCa

Few studies suggest RT for treatment of patients with oligometastatic bone disease in BCa (Table 2) (5-7,19,34). In these studies, only a single patient presented grade 3 acute dermatitis with grade ≥3 toxicity. Overall, patients received a high radiation dose that resulted in favorable outcomes, and mild toxicities. Here, Milano et al. (5) reported that the 5- and 10-year OS rates after SBRT were 83% and 75%, respectively, for bone-only patients vs. 31% and 17%, respectively, for other patients (P=0.002). Next, Rades et al. (20) suggest that the outcomes were most favorable in patients with myeloma/lymphoma followed by those with BCa, and that none of the BCa patients showed progression of motor deficits. Additionally, Yoo et al. (34) reported that high-dose RT (≥50 GyF10) and HER2-negative status were significantly associated with improved local control, and Takemoto et al. (7) reported that local recurrence was observed in a patient treated with 3 Gy ×10 irradiation, the lowest dose among the eleven patients.

In a prospective study by Owen et al. (16), 74 patients with non-spine bone oligometastases (inclusive of 8% BCa) treated with SBRT were administered 18 Gy or 24 Gy in a single fraction, or 30 Gy in 3 fractions. Of these, six patients with BCa did not present with local recurrence, although seven of 68 patients with other primary sites did. Also, the number of metastases at simulation (<5 vs. >5 metastases) was associated with reduced median OS post SBRT (10.8 vs. 6.4 months; P<0.0001). Next, in a retrospective study by Kobayashi et al. (35), 35 of 75 patients with oligometastatic BCa (39% bone) were treated with systemic chemotherapy plus metastasis-directed surgery or RT, and 40 patients were treated with systemic chemotherapy only. The 10- and 20-year OS rates were 82% and 53%, respectively in patients with multidisciplinary treatments vs. 42% and 23%, respectively in patients treated with systemic therapy alone (P=0.0063). Jacobson et al. (36) analyzed the number of sites of initial involvement identified in radionuclide bone scans in relation to long-term outcome in 113 BCa patients with bone as the sole initial site of metastatic disease. Median survival from time of recurrence and time of original diagnosis for the three bone scan categories was one lesion (n=47), 53 and 86 months; two lesions (n=22), 38 and 68 months; and ≥3 lesions (n=44), 22 and 58 months (P<0.0001 and P<0.005 for 1 and 2 lesions vs. ≥3).

Of note, none of the randomized clinical trials compares the effect of systemic chemotherapy plus RT with systemic chemotherapy alone for BCa patients with oligometastatic bone disease. However, the increased use of high-dose RT for treating oligometastatic bone disease, particularly in patients with BCa, as a “routine” option in many hospitals has made it difficult to conduct prospective randomized trials (37). The BCa expert panel of the German Society for Radiation Oncology and members of the Working Party of Gynecologic Oncology Breast Committee recommends a full dose-fractionated regimen, e.g., 2 Gy × 20–25 cycles, for RT of BCa patients with oligometastatic bone disease (8). Accordingly, by combining the results of RT for oligometastatic bone disease in other primary sites, we recommend high-dose RT or SBRT for BCa patients with oligometastatic bone disease.

Technically, the gross tumor volume (GTV) is the tumor visible in the magnetic resonance imaging (MRI) scans. In clinically suspected intradural extension, contrast-enhanced MRI is recommended to delineate the meningeval

### Table 2 RT for oligometastatic bone disease in BCa

<table>
<thead>
<tr>
<th>Author, year</th>
<th>No. of patients</th>
<th>RT dose and fractionation</th>
<th>Local control outcomes</th>
<th>Survival outcomes</th>
<th>Grade ≥3 toxicity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Milano et al. (5), 2019</td>
<td>12</td>
<td>5 Gy ×10, SBRT</td>
<td>100% (5 years)</td>
<td>83% (5 years)</td>
<td>0</td>
</tr>
<tr>
<td>Miyata et al. (6), 2017</td>
<td>17</td>
<td>40–74 Gy, in 1.8–2 Gy fractions</td>
<td>85% (5 years)</td>
<td>73% (5 years)</td>
<td>5.9%</td>
</tr>
<tr>
<td>Yoo et al. (34), 2015</td>
<td>31</td>
<td>20–60 Gy</td>
<td>66.2% (5 years)</td>
<td>61.6% (5 years)</td>
<td>NR</td>
</tr>
<tr>
<td>Takemoto et al. (7), 2009</td>
<td>11</td>
<td>2 Gy × (20–25), 3 Gy ×10</td>
<td>80% (5 years)</td>
<td>58.4% (5 years)</td>
<td>NR</td>
</tr>
<tr>
<td>Rades et al. (20), 2007</td>
<td>149</td>
<td>8 Gy ×1, 3 Gy ×10, 2 Gy ×20</td>
<td>79% (3 years)</td>
<td>51% (3 years)</td>
<td>0</td>
</tr>
</tbody>
</table>

RT, radiation therapy; BCa, breast cancer; SBRT, stereotactic body radiotherapy; NR, not reported.
enhancement and is included in the GTV. The clinical target volume (CTV) includes the GTV with an adequate (e.g., 1–2 cm) margin. Of note, the CTV should always include the complete vertebral body in case of vertebral body involvement. In the case of unaffected compacta, extension of the CTV beyond the compacta is discouraged (8). The planning target volume (PTV) margin differs based on factors such as the use of image-guided radiotherapy (IGRT) or not, the method of IGRT, reproducibility, and respiratory motion. Furthermore, the three-dimensional (3D) treatment planning is essential, especially for lesions of the trunk, because the treatment of oligometastatic bone disease requires high-dose RT and checking the irradiated dose and volume of adjacent normal tissue.

**Future perspectives**

Based on the current scenario, combined use of RT and immune checkpoint inhibitors (ICI) may enhance the antitumor immune response and produce a synergistic effect (38). The randomized double-blind international phase III PACIFIC trial (39) compared the effect of durvalumab as consolidation therapy with placebo in 713 patients with stage III locally advanced unresectable non-small cell lung cancer after treatment with platinum-based definitive chemoradiotherapy. The 24-month OS rate was 66.3% in the durvalumab group, as compared to 55.6% in the placebo group (two-sided P=0.005). Durvalumab significantly prolonged OS, as compared with placebo (stratified hazard ratio for death, 0.68; P=0.0025). Chicas-Sett et al. in their systematic review discussed the effect of combined RT and ipilimumab in patients with metastatic melanoma (40), where a survival benefit of eight months in favor of the RT plus ipilimumab combination was observed in comparison with the median OS of 11.4 months in the pooled analysis of phase II and III trials of ipilimumab without RT.

Furthermore, there are several ongoing and completed clinical trials combining RT and ICI in metastatic BCa patients (41). In future, the combined use of RT and ICI may serve as a promising therapeutic option against oligometastatic bone disease in BCa.

**Conclusions**

Based on results from several studies, the overall survival of BCa patients with oligometastatic bone disease is favorable compared to those with metastatic bone disease. Furthermore, we recommend high-dose RT or SBRT for patients with oligometastatic bone disease. The use of MRI for proper target volume definition and 3D treatment planning especially for lesions of the trunk are essential for the treatment planning of RT. Finally, we anticipate that combinatorial treatment using RT and ICI may benefit BCa patients with oligometastatic bone disease.

**Acknowledgments**

**Funding:** None.

**Footnote**

Provenance and Peer Review: This article was commissioned by the Guest Editors (Tadahiko Shien and Kaori Terata) for the series “Loco regional therapy for metastatic breast cancer” published in *Translational Cancer Research*. The article was sent for external peer review organized by the Guest Editors and the editorial office.

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tcr.2020.01.35). The series “Loco-regional therapy for metastatic breast cancer” was commissioned by the editorial office without any funding or sponsorship. The authors have no other conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

**References**

2. Coleman RE. Clinical features of metastatic bone


1:16-25.


